Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash & Current Investments: 2011-2025

Historic Cash & Current Investments for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to $188.9 million.

  • Enanta Pharmaceuticals' Cash & Current Investments fell 23.90% to $188.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $803.0 million, marking a year-over-year decrease of 28.03%. This contributed to the annual value of $188.9 million for FY2025, which is 23.90% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Cash & Current Investments stood at $188.9 million for FY2025, which was down 23.90% from $248.2 million recorded in FY2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Cash & Current Investments peaked at $369.9 million during FY2023, and registered a low of $188.9 million during FY2025.
  • Its 3-year average for Cash & Current Investments is $269.0 million, with a median of $248.2 million in 2024.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first slumped by 36.89% in 2021, then skyrocketed by 48.42% in 2023.
  • Yearly analysis of 5 years shows Enanta Pharmaceuticals' Cash & Current Investments stood at $244.0 million in 2021, then grew by 2.14% to $249.2 million in 2022, then skyrocketed by 48.42% to $369.9 million in 2023, then slumped by 32.91% to $248.2 million in 2024, then decreased by 23.90% to $188.9 million in 2025.